| Recruiting | CLF065 for Chronic Pouchitis NCT07226050 | Calibr, a division of Scripps Research | Phase 2 |
| Not Yet Recruiting | Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications NCT07240649 | Jay C. Buckey Jr. | Phase 4 |
| Not Yet Recruiting | Etrasimod as Prevention of Pouchitis NCT07486921 | Maia Kayal | Phase 2 |
| Not Yet Recruiting | GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis NCT06916390 | Universitaire Ziekenhuizen KU Leuven | Phase 4 |
| Recruiting | Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch NCT06864403 | University of North Carolina, Chapel Hill | Phase 4 |
| Not Yet Recruiting | Exploring the Influence of Trptophan on the Treatment of Pouchitis NCT06861140 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Recruiting | A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active C NCT06443502 | Takeda | Phase 3 |
| Recruiting | Fecal Microbiota Transplant for Patients With Chronic Pouchitis NCT05829109 | Maia Kayal | EARLY_Phase 1 |
| Completed | Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis NCT06316999 | Mayo Clinic | N/A |
| Recruiting | Rifaximin for the Secondary Prevention of Recurrent Pouchitis NCT06312683 | University of North Carolina, Chapel Hill | Phase 4 |
| Withdrawn | Stem Cells for the Treatment of Pouchitis NCT05578508 | The Cleveland Clinic | Phase 1 |
| Terminated | Efficacy of Liraglutide Therapy in Patients With IPAA NCT04763564 | University of North Carolina, Chapel Hill | Phase 2 |
| Suspended | Assessment of Patients With Acute Pouchitis Treated With Antibiotics NCT05252273 | Alimentiv Inc. | — |
| Unknown | GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surge NCT04979832 | Zealand University Hospital | Phase 1 / Phase 2 |
| Completed | Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis NCT04820413 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | N/A |
| Completed | Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis NCT04741087 | Applied Molecular Transport | Phase 2 |
| Terminated | Tofacitinib For Treatment Of Chronic Pouchitis NCT04580277 | Cedars-Sinai Medical Center | Phase 2 |
| Withdrawn | Treating Chronic Pouchitis With a Low FODMAP Diet NCT04640155 | Northwestern University | N/A |
| Completed | Stelara fOr ChRonic AntibioTic rEfractory pouchitiS NCT04089345 | Universitaire Ziekenhuizen KU Leuven | Phase 3 |
| Unknown | Prospective Dietary Therapy Using Crohn's Disease Exclusion Diet for Ileal Pouch Anal Anastomosis Patients NCT04327219 | Tel-Aviv Sourasky Medical Center | N/A |
| Active Not Recruiting | the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis NCT03524352 | Nantes University Hospital | Phase 3 |
| Terminated | The Role of Secondary Bile Acids in Intestinal Inflammation NCT03724175 | Stanford University | Phase 2 / Phase 3 |
| Recruiting | Inflammatory Bowel Diseases Remission Registry NCT04912999 | Tel-Aviv Sourasky Medical Center | — |
| Unknown | Inflammatory Bowel Diseases (IBD) Cannabis Registry NCT05578313 | Eli Sprecher, MD | — |
| Terminated | Faecal Microbiota Transplantation in the Treatment of Chronic Pouchitis NCT04100291 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | N/A |
| Recruiting | Fecal Microbiota Transplantation for Pouchitis NCT03545386 | McMaster University | Phase 2 |
| Unknown | Advanced Therapy Registry of IBD Patients NCT04998084 | Tel-Aviv Sourasky Medical Center | — |
| Unknown | Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis NCT03526796 | Jinling Hospital, China | N/A |
| Completed | Fecal Microbiota Transplantation for Chronic Pouchitis NCT03538366 | Aalborg University Hospital | N/A |
| Completed | Fecal Microbiota Transplantation (FMT) in the Treatment of Pouchitis NCT03378921 | Helsinki University Central Hospital | Phase 2 |
| Terminated | Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchit NCT02782325 | University of North Carolina, Chapel Hill | Phase 1 / Phase 2 |
| Unknown | Microbiota and Immune microEnvironment in Pouchitis NCT03136419 | University of Padova | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis NCT02790138 | Takeda | Phase 4 |
| Completed | Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA NCT02828410 | Boston Medical Center | N/A |
| Completed | Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics NCT02525523 | Atlantic Pharmaceuticals Ltd | Phase 3 |
| Completed | Fecal Microbiota Transplant (FMT) for Pouchitis NCT02428361 | Najwa Elnachef | EARLY_Phase 1 |
| Completed | To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis NCT02201186 | Dr. Carl J Brown | Phase 2 |
| Completed | Study of Sc-FOS for Pouchitis Prevention NCT02203955 | Mayo Clinic | Phase 1 |
| Completed | Adalimumab in the Treatment of Chronic Pouchitis NCT01670240 | Odense University Hospital | Phase 3 |
| Unknown | The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of P NCT01202396 | Maastricht University Medical Center | — |
| Completed | Surgical Reconstruction in Ulcerative Colitis With Primary Sclerosing Cholangitis NCT01798953 | Sahlgrenska University Hospital | — |
| Terminated | Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis NCT00583531 | Ocera Therapeutics | Phase 2 |
| Completed | Safety and Efficacy of AST-120 in the Treatment of Pouchitis NCT00583076 | Ocera Therapeutics | Phase 2 |
| Terminated | Clotrimazole Enemas for Pouchitis in Children and Adults NCT00061282 | Web | Phase 1 / Phase 2 |
| Completed | Clinical Approaches to Ileal Pouch Dysfunction NCT00293553 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 |